New hope for bile duct cancer: maintenance therapy trial launches
NCT ID NCT07269158
First seen Dec 18, 2025 · Last updated Apr 25, 2026 · Updated 22 times
Summary
This study is for people with advanced biliary tract cancer whose disease is under control after initial chemotherapy and immunotherapy. It tests whether adding different drugs (lenvatinib, venadaparib, or IL-2) to ongoing immunotherapy can keep the cancer from growing longer than immunotherapy alone. The goal is to find a better maintenance strategy to extend survival and improve quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine, Korea
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.